Evidence map›Paper›PMID 40341182›Full record

ReviewRMD open2025

Time sequence of autoimmune processes in the trajectory to rheumatoid arthritis development: what do we know?

Judith W Heutz, René E M Toes, Annette H M van der Helm-van Mil

Abstract readReview
In one paragraph

Review in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Antibiotics for Rheumatologic Diseases: A Critical Review.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Judith W HeutzDepartment of Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands j.heutz@erasmusmc.nl.ORCID 0000-0002-2126-7922
René E M ToesDepartment of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.ORCID 0000-0002-9618-6414
Annette H M van der Helm-van MilDepartment of Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.ORCID 0000-0001-8572-1437

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The trajectory to RA development is a multi-step process that can take a decade. Understanding which processes occur at which moment during this trajectory is crucial when designing interventions to prevent disease development. Clinically, the period before RA onset can be divided into an asymptomatic and a symptomatic risk phase. Published visual representations of RA development often display the maturation of the autoimmune response occurring in the symptomatic risk phase or relatively short before RA development, but evidence underlying this notion is limited. To obtain more detailed insights into the time sequence of immune processes in the asymptomatic and symptomatic risk stages of RA development, we interpreted the current available literature against the level of evidence, as longitudinal studies with repeated measurements in patients are needed for a robust conclusion on temporal sequences. Regarding the development of ACPA-positive disease, maturation of the systemic autoimmune response seems to occur approximately 5-years before diagnosis, but the autoimmune response is stable during the symptomatic risk phase and progression to RA. Known genetic and environmental factors have a different effect in both risk phases. Less is known about the development of ACPA-negative RA, the symptomatic risk phase lasts longer than for ACPA-positive RA, but here too the maturation of the autoimmunity seems to take place mainly in the asymptomatic phase. Based on this, we have proposed a new picture of RA development. This knowledge can guide the choice of treatment targets in future trials aimed at preventing RA.

Indexed as

Arthritis, RheumatoidAutoimmunityAnti-Citrullinated Protein AntibodiesAutoantibodiesDisease ProgressionHumansRisk FactorsTime FactorsAnti-Citrullinated Protein AntibodiesAutoantibodiesAnti-Citrullinated Protein AntibodiesArthritis, RheumatoidAutoimmunityCytokines

Identifiers

PMID40341182
PMCPMC12060877

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.